SEOUL, Oct. 14 (UPI) -- South Korea's Hyundai ADM Bio said Tuesday that its new cancer drug under development, Penetrium, also may prove effective treating such diseases as rheumatoid arthritis and multiple sclerosis.
In July, Hyundai ADM Bio announced that the new-concept medicine was designed to enhance the efficiency of traditional cancer treatments by targeting the supportive structure around cancer cells, known as the tumor microenvironment.
The Seoul-based company plans to disclose the findings at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which be held in Boston later this month.
Hyundai ADM Bio noted that it will share preclinical trial results of Penetrium involving various cancers as well as four other diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis and Crohn's disease.
Related
